Major Depressive Disorder In The Elderly

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 3

Conditions: Depressive Disorder, Major

Treatments: Drug: bupropion XL

Study type: Interventional

Funder types: Industry

Identifiers

NCT00093288

AK130940

Details and patient eligibility

About

This is a placebo-controlled study evaluating the effectiveness of medication in elderly subjects with Major Depressive Disorder (MDD).

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Primary diagnosis of Major Depressive Disorder with DSM-IV criteria for their current episode for at least 8 weeks.

Exclusion criteria

• Patient has current or past history of seizure disorder or brain injury.
• Patient has a diagnosis of anorexia or bulimia within the past 12 months.
• Patient has a past or current DMS-IV diagnosis of schizophrenia or any other psychotic disorder(s).
• Patient has had a myocardial infarction within 1 year or a history of uncontrolled hypertension or unstable heart disease with 6 months.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind